Hansa Biopharma AB (HNSA) - Financial and Strategic SWOT Analysis Review

May 2019 | 47 pages | ID: H77D9C99E44EN
GlobalData

Abstracts

Hansa Biopharma AB (HNSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hansa Biopharma AB (Hansa Biopharma) is a biopharmaceutical company. It focuses on the development of novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company's lead project, IdeS is a proprietary antibody-degrading enzyme in late stage clinical development for kidney transplant patients. IdeS has potential for further development in other solid organ transplants and a range of acute autoimmune indications. Its preclinical assets include NiceR for recurring treatment in autoimmune disease, transplantation and cancer; and EnzE, a cancer immunotherapy. Hansa Biopharma out-licensed its HBP-assay (serum quantification of Heparin-Binding Protein), a novel diagnostic method to help predict severe sepsis in patients with infectious disease symptoms to Axis-Shield Diagnostics. Hansa Biopharma is headquartered in Lund, Sweden.

Hansa Biopharma AB Key Recent Developments

Apr 29,2019 Hansa Biopharma Interim Report January–March 2019
Apr 29,2019 Hansa Biopharma expands leadership team with dedicated roles for Corporate Communications, Investor Relations and Business Development
Feb 08,2019 Regulatory press release: Hansa Biopharma Year-End Report 2018
Feb 08,2019 Hansa Biopharma year-end report 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Hansa Biopharma AB - Key Facts
Hansa Biopharma AB - Key Employees
Hansa Biopharma AB - Key Employee Biographies
Hansa Biopharma AB - Major Products and Services
Hansa Biopharma AB - History
Hansa Biopharma AB - Company Statement
Hansa Biopharma AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Hansa Biopharma AB - Business Description
Hansa Biopharma AB - Corporate Strategy
Hansa Biopharma AB - SWOT Analysis
SWOT Analysis - Overview
Hansa Biopharma AB - Strengths
Hansa Biopharma AB - Weaknesses
Hansa Biopharma AB - Opportunities
Hansa Biopharma AB - Threats
Hansa Biopharma AB - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Hansa Biopharma AB, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 29, 2019: Hansa Biopharma Interim Report January–March 2019
Apr 29, 2019: Hansa Biopharma expands leadership team with dedicated roles for Corporate Communications, Investor Relations and Business Development
Feb 08, 2019: Regulatory press release: Hansa Biopharma Year-End Report 2018
Feb 08, 2019: Hansa Biopharma year-end report 2018
Feb 07, 2019: Hansa Biopharma names Donato Spota as new chief financial officer
Jan 18, 2019: Hansa Medical announces appointment of Anne Safstrom Lanner as vice president, global human resources
Dec 20, 2018: Hansa Medical to change name to Hansa Biopharma
Dec 11, 2018: Bulletin from the Extraordinary General Meeting of Hansa Medical AB

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Hansa Biopharma AB, Key Facts
Hansa Biopharma AB, Key Employees
Hansa Biopharma AB, Key Employee Biographies
Hansa Biopharma AB, Major Products and Services
Hansa Biopharma AB, History
Hansa Biopharma AB, Subsidiaries
Hansa Biopharma AB, Key Competitors
Hansa Biopharma AB, Ratios based on current share price
Hansa Biopharma AB, Annual Ratios
Hansa Biopharma AB, Annual Ratios (Cont...1)
Hansa Biopharma AB, Interim Ratios
Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Hansa Biopharma AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Hansa Biopharma AB, Performance Chart (2014 - 2018)
Hansa Biopharma AB, Ratio Charts
Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

TikoMed AB
Fastilium Property Group AB
Active Biotech AB
Calliditas Therapeutics AB
iCell Science AB
BioInvent International AB
Swedish Orphan Biovitrum AB
Mertiva AB